Obio Technology (shanghai) Corp Ltd
688238
Company Profile
Business description
Obio Technology (shanghai) Corp Ltd is a biotechnology company focusing on the field of gene therapy, focusing on the development of gene therapy vectors, gene function research, drug targets and efficacy for the basic research of gene therapy Research and other CRO services, and provide CDMO services such as process development and testing, IND-CMC pharmaceutical research, and clinical sample GMP production for the research and development of genetic drugs.
Contact
Lane 908, Ziping Road
Building 19
International Medical Park, Pudong New Area
Shanghai201321
CHNT: +86 2158585887
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
692
Stocks News & Analysis
stocks
We remove our Moat Rating from ASX listed share
Despite a surging share price a weakening competitive position causes a reassessment of our view.
stocks
Best sustainable companies to own in 2026
We believe these companies’ strong ESG management practices give them a long-term advantage.
stocks
New data centre deal for ASX listed REIT
New parternship adds to a growing data centre pipeline in fiscal 2026.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,034.70 | 2.20 | -0.02% |
| CAC 40 | 8,201.99 | 6.78 | 0.08% |
| DAX 40 | 24,719.31 | 179.97 | 0.73% |
| Dow JONES (US) | 48,382.39 | 319.10 | 0.66% |
| FTSE 100 | 9,963.77 | 12.63 | 0.13% |
| HKSE | 26,347.24 | 8.77 | 0.03% |
| NASDAQ | 23,235.63 | 6.36 | -0.03% |
| Nikkei 225 | 51,832.80 | 1,493.32 | 2.97% |
| NZX 50 Index | 13,587.23 | 38.81 | 0.29% |
| S&P 500 | 6,858.47 | 12.97 | 0.19% |
| S&P/ASX 200 | 8,728.60 | 2.60 | 0.03% |
| SSE Composite Index | 4,023.42 | 54.58 | 1.38% |